Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) and XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.
Profitability
This table compares Karyopharm Therapeutics and XTL Biopharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Karyopharm Therapeutics | -129.02% | N/A | -120.29% |
| XTL Biopharmaceuticals | N/A | N/A | N/A |
Earnings & Valuation
This table compares Karyopharm Therapeutics and XTL Biopharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Karyopharm Therapeutics | $146.07 million | 1.10 | -$196.04 million | ($15.09) | -0.47 |
| XTL Biopharmaceuticals | $450,000.00 | 13.76 | -$6.97 million | ($0.64) | -4.40 |
XTL Biopharmaceuticals has lower revenue, but higher earnings than Karyopharm Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings for Karyopharm Therapeutics and XTL Biopharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Karyopharm Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
| XTL Biopharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Karyopharm Therapeutics currently has a consensus target price of $16.67, suggesting a potential upside of 135.07%. Given Karyopharm Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Karyopharm Therapeutics is more favorable than XTL Biopharmaceuticals.
Volatility and Risk
Karyopharm Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
Insider and Institutional Ownership
66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
